What Analysts Are Saying About Crinetics Pharmaceuticals Stock
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a recent average price target of $77.17, reflecting a 3.35% increase. The company faces financial challenges with a significant revenue decline and negative net margin, but maintains a strong market position with a low debt-to-equity ratio.
September 27, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Crinetics Pharmaceuticals (CRNX) has received mixed analyst ratings with a slight increase in the average price target to $77.17. The company faces financial challenges, including a significant revenue decline and negative net margin, but maintains a strong market position with a low debt-to-equity ratio.
The mixed analyst ratings and slight increase in price target suggest a neutral short-term impact on CRNX stock. The company's financial challenges, such as revenue decline and negative net margin, are balanced by its strong market position and low debt-to-equity ratio, leading to a neutral outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100